JP2016515615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515615A5 JP2016515615A5 JP2016506281A JP2016506281A JP2016515615A5 JP 2016515615 A5 JP2016515615 A5 JP 2016515615A5 JP 2016506281 A JP2016506281 A JP 2016506281A JP 2016506281 A JP2016506281 A JP 2016506281A JP 2016515615 A5 JP2016515615 A5 JP 2016515615A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyl
- composition according
- hydrogen
- alkyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 63
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 150000002431 hydrogen Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- FEIQOMCWGDNMHM-KBXRYBNXSA-N (2e,4e)-5-phenylpenta-2,4-dienoic acid Chemical compound OC(=O)\C=C\C=C\C1=CC=CC=C1 FEIQOMCWGDNMHM-KBXRYBNXSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229940074360 caffeic acid Drugs 0.000 claims description 3
- QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 3
- 235000004883 caffeic acid Nutrition 0.000 claims description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 2
- -1 isoprenyl Chemical group 0.000 claims description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 49
- 238000011275 oncology therapy Methods 0.000 description 26
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- CUGDOWNTXKLQMD-BQYQJAHWSA-N Pinostrobin chalcone Chemical compound OC1=CC(OC)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 CUGDOWNTXKLQMD-BQYQJAHWSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- CUGDOWNTXKLQMD-UHFFFAOYSA-N Pinostrobinchalkon Natural products OC1=CC(OC)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 CUGDOWNTXKLQMD-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- DZAPHTCUSDTZAT-CSKARUKUSA-N benzyl (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)OCC=2C=CC=CC=2)=C1 DZAPHTCUSDTZAT-CSKARUKUSA-N 0.000 description 2
- DZAPHTCUSDTZAT-UHFFFAOYSA-N benzyl ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OCC=2C=CC=CC=2)=C1 DZAPHTCUSDTZAT-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 0 C*(CC=[S@](C)*=O)c1cc(N=O)c(*)cc1 Chemical compound C*(CC=[S@](C)*=O)c1cc(N=O)c(*)cc1 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ609106 | 2013-04-05 | ||
| NZ60910613 | 2013-04-05 | ||
| PCT/NZ2014/000059 WO2014163512A1 (en) | 2013-04-05 | 2014-04-07 | Therapeutic compositions comprising extracts of propolis and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515615A JP2016515615A (ja) | 2016-05-30 |
| JP2016515615A5 true JP2016515615A5 (enExample) | 2017-07-06 |
| JP6444984B2 JP6444984B2 (ja) | 2018-12-26 |
Family
ID=51658695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506281A Active JP6444984B2 (ja) | 2013-04-05 | 2014-04-07 | プロポリス抽出物を含む治療組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160030364A1 (enExample) |
| EP (1) | EP2981254B1 (enExample) |
| JP (1) | JP6444984B2 (enExample) |
| CN (1) | CN105163728B (enExample) |
| AU (1) | AU2014250138B2 (enExample) |
| TW (1) | TW201517901A (enExample) |
| WO (1) | WO2014163512A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2983681B1 (en) | 2013-04-05 | 2020-07-15 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
| TW201609113A (zh) * | 2014-07-18 | 2016-03-16 | 歐文 約翰 蓋奇波 | 治療組合物及其用途 |
| RU2568876C1 (ru) * | 2015-02-11 | 2015-11-20 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Способ определения оксима пиностробина в плазме крови |
| JP2019515943A (ja) * | 2016-03-24 | 2019-06-13 | マヌカ ヘルス ニュージーランド リミテッド | 治療用組成物およびその使用 |
| CN106913873A (zh) * | 2017-04-26 | 2017-07-04 | 中国药科大学 | 巴西绿蜂胶在制备pdt抗肿瘤的协同增效药物中的应用 |
| WO2020086830A2 (en) * | 2018-10-26 | 2020-04-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN109912607B (zh) * | 2018-12-11 | 2021-01-22 | 南华大学 | 一类卟啉-白杨素复合物及其抗肿瘤活性 |
| US20220370385A1 (en) * | 2019-09-17 | 2022-11-24 | Enzene Biosciences Ltd. | Compositions for use in inhibiting src kinase and treating and preventing associated disorders |
| CN116492324A (zh) * | 2023-01-04 | 2023-07-28 | 河南科技大学第一附属医院 | 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| WO2002047615A2 (en) * | 2000-12-13 | 2002-06-20 | University Of Rochester | Oral compositions and use thereof |
| US6689811B2 (en) * | 2001-04-20 | 2004-02-10 | Wake Forest University | Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers |
| JP2003119169A (ja) * | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
| US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
| KR100968367B1 (ko) * | 2006-10-02 | 2010-07-06 | 재단법인서울대학교산학협력재단 | 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물 |
| CN101502506B (zh) * | 2009-02-24 | 2011-08-17 | 连晓媛 | 咖啡酸3,4-二羟基苯乙酯的医药用途 |
| WO2011156889A1 (en) * | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| CN101875648B (zh) * | 2010-07-12 | 2012-12-12 | 马灵媛 | 一种从药用植物中提取纯化球松素的方法及其药物制剂与应用 |
| WO2013022740A2 (en) * | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
| WO2013078371A2 (en) * | 2011-11-22 | 2013-05-30 | The Johns Hopkins University | Methods and compositions for reducing alcohol toxicity |
| CN102949384A (zh) * | 2012-10-29 | 2013-03-06 | 浙江大学 | 咖啡酸3，4-二羟基苯乙酯在制备抗肿瘤药物中的应用 |
| CN104016862A (zh) * | 2013-02-28 | 2014-09-03 | 北京大学 | 咖啡酸苯乙酯酚羟基保护衍生物的制备及其作为神经保护剂和抗肿瘤药物的应用 |
| EP2983681B1 (en) * | 2013-04-05 | 2020-07-15 | Manuka Health New Zealand Limited | Therapeutic compositions and uses thereof |
-
2014
- 2014-04-07 CN CN201480022371.8A patent/CN105163728B/zh active Active
- 2014-04-07 AU AU2014250138A patent/AU2014250138B2/en active Active
- 2014-04-07 EP EP14779926.6A patent/EP2981254B1/en active Active
- 2014-04-07 US US14/781,860 patent/US20160030364A1/en not_active Abandoned
- 2014-04-07 WO PCT/NZ2014/000059 patent/WO2014163512A1/en not_active Ceased
- 2014-04-07 JP JP2016506281A patent/JP6444984B2/ja active Active
- 2014-04-07 TW TW103112675A patent/TW201517901A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515615A5 (enExample) | ||
| JP2016516751A5 (enExample) | ||
| Bhuvaneswari et al. | Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response | |
| JP2015520753A5 (enExample) | ||
| JP2016224056A5 (enExample) | ||
| MX349996B (es) | Metodos y composiciones para diagnostico y tratamiento del cancer. | |
| JP2015500225A5 (enExample) | ||
| JP2009513662A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| JP2016519107A5 (enExample) | ||
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2019507764A5 (enExample) | ||
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| Liu et al. | Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells | |
| WO2009067520A3 (en) | Peptides specific for hepatocellular carcinoma cells and applications thereof | |
| WO2011094260A3 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
| Huang et al. | Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer | |
| US20210145811A1 (en) | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype | |
| CN109562093A (zh) | 含peitc的药物组合物及其在癌症治疗中的应用 | |
| JP2014524479A5 (enExample) | ||
| O’kane et al. | Vismodegib in the treatment of advanced BCC | |
| Osada et al. | Growth inhibition of unresectable tumors induced by hepatic cryoablation: report of two cases | |
| Dearnaley et al. | Escalated-dose Conformai radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial |